The effect of metastatic site and decade of diagnosis on the individual burden of metastatic melanoma: Contemporary estimates of average years of life lost

Cancer Investigation

Volumn 30, Issue 9, 2012, Pages 637-641

  Salama, April K S ^a,b   Rosa, Nicole De ^b   Scheri, Randall P ^a,b,c   Herndon, James E ^a,b   Tyler, Douglas S ^a,b,c   Marcello, Jennifer ^a   Pruitt, Scott K ^a,b,c   Abernethy, Amy P ^a,b  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

Author keywords

Life expectancy; Melanoma; Mortality; Potential years of life lost; Survival

Indexed keywords

ADULT; AGED; ARTICLE; AVERAGE YEARS OF LIFE LOST; BONE METASTASIS; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; FEMALE; GROUPS BY AGE; HUMAN; LIFE EXPECTANCY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN METASTASIS;

AGE FACTORS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LIFE EXPECTANCY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 84867721516     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.726387     Document Type: Article

References (24)

1. Siegel R,NaishadhamD, JemalA. Cancer statistics, 2012.CACancer J Clin 2012;62:10-29.
2. Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999;40:35-42.
3. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907.
4. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Critical Reviews in Oncology/Hematology 2010;74:27-39.
5. Surveillance, Epidemiology and End Results (SEER) Program. National Cancer Institute 2003-2007. http://seer.cancer.gov/statfacts/html/melan.html, accessed February 3, 2011.
6. http://fundedresearch.cancer.gov/, accessed August 9, 2012.
7. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP. Years of life lost (YLL) from cancer is an important measure of population burden-and should be considered when allocating research funds. Br J Cancer 2005;92:241-245.
8. Ekwueme DU, Guy GP, Jr., Li C, Rim SH, Parelkar P, Chen SC. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity-United States, 2000 to 2006. JAmAcad Dermatol 2011;65:S133-S143.
9. Guy GP, Ekwueme DU. Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature. Pharmacoeconomics 2011;29:863-874.
10. Yabroff KR, Bradley CJ, Mariotto AB, Brown ML, Feuer EJ. Estimates and projections of value of life lost from cancer deaths in the United States. J Natl Cancer Inst 2008;100:1755-1762.
11. Horm JW, Sondik EJ. Person-years of life lost due to cancer in the United States, 1970 and 1984. Am J Public Health 1989;79:1490-1493.
12. Taylor D, Nyambose JKK, D. Earle CC, Thompson D. Impact of mortality due to malignantmelanoma versus other cancers. J Clin Oncol 2008;26: (May 20 suppl; abstr 20016) 2008.
13. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27:6199-6206.
14. RhodesAR. Public education and cancer of the skin.What do people need to know about melanoma and nonmelanoma skin cancer? Cancer 1995;75:613-636.
15. Wagner JD, Bergman D. Primary cutaneous melanoma: surgical management and other treatment options. Curr Treat Options Oncol 2003;4:177-185.
16. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6(Suppl 1):S11-S14.
17. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K; Melanoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev 2007;33:484-496.
18. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4: 748-759.
19. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazinebased chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19:21-34.
20. Hodi FS, O'Day SJ, McDermott DF,Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebb́e C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 2010;363:711-723.
21. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. N Engl J Med 2011;364(26):2507-2516.
22. Hodi FS,ObleDA, Drappatz J,Velazquez EF, RamaiyaN, Ramakrishna N, Day AL, Kruse A,Mac Rae S, Hoos A,Mihm M. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008;5:557-561.
23. Flaherty KT, Puzanov I, KimKB, Ribas A,McArthur GA, Sosman JA, O'DwyerPJ, LeeRJ, Grippo JF,NolopK, ChapmanPB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
24. Eggermont AM. Advances in systemic treatment of melanoma. Ann Oncol 2010;21(Suppl 7): vii339-vii344.